Clinical trial technology: at the inflection point

Paul Bleicher
{"title":"Clinical trial technology: at the inflection point","authors":"Paul Bleicher","doi":"10.1016/S1478-5382(03)02373-4","DOIUrl":null,"url":null,"abstract":"<div><p>Paper-based methods of clinical data collection, analysis and management have long been standard practice, but the development of online software solutions and the ubiquitous presence of the internet create opportunities to improve these processes. Adoption rates of the new technologies have been slow as result of in part resistance to change, but use of electronic solutions is on the upswing. The industry's overriding interest in accelerating clinical development of lead compounds, a newly supportive environment from the Food and Drug Administration, the presence of maturing technology and the emergence of stable vendors are the confluence of factors driving an inflection point.</p></div>","PeriodicalId":9227,"journal":{"name":"Biosilico","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2003-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1478-5382(03)02373-4","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biosilico","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1478538203023734","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Paper-based methods of clinical data collection, analysis and management have long been standard practice, but the development of online software solutions and the ubiquitous presence of the internet create opportunities to improve these processes. Adoption rates of the new technologies have been slow as result of in part resistance to change, but use of electronic solutions is on the upswing. The industry's overriding interest in accelerating clinical development of lead compounds, a newly supportive environment from the Food and Drug Administration, the presence of maturing technology and the emergence of stable vendors are the confluence of factors driving an inflection point.

临床试验技术:处于拐点
长期以来,基于纸张的临床数据收集、分析和管理方法一直是标准做法,但在线软件解决方案的发展和无处不在的互联网为改进这些流程创造了机会。新技术的采用率一直缓慢,部分原因是对变革的抵制,但电子解决方案的使用正在上升。制药行业对加速先导化合物临床开发的极大兴趣、美国食品和药物管理局(fda)的新支持环境、成熟技术的存在以及稳定供应商的出现,这些因素共同推动了一个拐点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信